{
  "docId": "019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "docSlug": "8f301a1a54ee099c965687c909e40052",
  "documentTitle": "Equillium | Investor Presentation Deck | 40 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 40,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a process-like flow to highlight 'reduce inflammation' as the key target, supported by logos of major pharma companies.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-cd1b-731e-ae5e-e1dc823ccd70/33",
  "deckHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "deckJsonHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70.json",
  "deckAnchorHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "callout",
      "text": "EQ302 selectively targets the underlying immune pathophysiology, and the targeted approach aligns with FDA guidance to treat inflammation",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca05741f-8925-4b91-b1d8-78755e22faa4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.03,
        "y": 0.035
      },
      "kind": "diagram",
      "text": "Approaches to Treating Celiac Disease: gluten modification, restore gut barrier function, promote immune tolerance, reduce inflammation (IL-15/IL-21)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30c9df75-72d7-4f7d-a5f4-a6076f4e411c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.045
      },
      "kind": "image",
      "text": "Amgen, Pfizer, Novartis, Takeda",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50f46812-331c-45ff-9568-64ee4b469464",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.7,
        "y": 0.08
      },
      "kind": "paragraph",
      "text": "FDA guidance was recently updated and provides clear guidelines for path to approval. Emphasis has been placed on development of effective anti-inflammatory strategies.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8edff9f0-8a2b-4f18-b690-903916e1c3d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.03,
        "y": 0.075
      },
      "kind": "paragraph",
      "text": "IL-15 a validated target in the treatment of celiac disease with IL-15 inhibition alone having shown some efficacy but results suggest that dual inhibition of IL-15 and IL-21 may have superior effect.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f641cb78-b160-4d54-898e-f3758922460b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Opportunity in Celiac Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95607e7c-b2a0-43ac-a994-463f0f3d4742",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Hypothesis-Driven Structure",
      "slug": "hypothesis-driven-structure",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "6640c49e-c6a9-4af2-b249-e85d89950af5",
      "evidence": "The slide presents a hypothesis-driven approach to treating celiac disease, with EQ302 selectively targeting the underlying immune pathophysiology.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}